BOSTON, October 21, 2026 – Noah Labs today announced the start of VOICE-HF, a prospective, multicenter pivotal study of Noah Labs Vox™ in adults with stage C chronic heart failure. The first participants were enrolled at Brigham and Women’s Hospital in Boston, Massachusetts, part of Mass General Brigham and a teaching affiliate of Harvard Medical School (Principal Investigator: Ameesh M. Isath, MD), and at Minneapolis Heart Institute Foundation® at Abbott Northwestern Hospital in Minneapolis, Minnesota (Principal Investigator: Mosi K. Bennett, MD, PhD).
Most patients have no structured monitoring at home. Daily weight scales, the most common home tool, have limited sensitivity because congestion often begins with fluid redistribution before body weight rises. When scales do signal deterioration, it is often only a few days before a hospitalization. Implantable cardiac sensors detect congestion earlier but require an invasive, costly procedure and reach only a small fraction of eligible patients. Congestion also affects the lungs, airways, and vocal folds, producing subtle but measurable changes in the voice. Noah Labs Vox™ is cloud-based software designed to detect these changes from short voice recordings captured at home on a phone or tablet, with the aim of extending remote monitoring and management to as many patients with heart failure as possible.
Each participant records a short daily voice sample on their smartphone or tablet at home. Noah Labs Vox™ analyzes the recordings for signs of worsening heart failure. The study includes more than 15 sites in the US, Europe, and Canada. The co-primary endpoints are sensitivity for worsening heart failure events and the unexplained alert rate. VOICE-HF is led by National Principal Investigator Aman Shah, MD, an advanced heart failure and transplant cardiologist at Tampa General Hospital’s Heart & Vascular Institute.